Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BMXMF OTCMKTS:CHEOY NYSE:LH NASDAQ:NTRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMXMFbioMerieux$140.25$143.81$100.50▼$152.00$16.60B0.74106 shsN/ACHEOYCochLear$97.62+1.1%$99.53$74.76▼$105.60$12.88B0.922,123 shs23,075 shsLHLabcorp$273.49-0.1%$263.61$209.38▼$283.47$23.10B0.85454,961 shs383,623 shsNTRANatera$167.53-1.1%$154.38$110.57▼$183.00$23.09B1.681.45 million shs1.10 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMXMFbioMerieux0.00%-4.72%-2.74%+3.13%+20.73%CHEOYCochLear+1.11%-1.61%-3.58%+8.86%-1.99%LHLabcorp-0.20%-2.17%+3.67%+8.44%+19.05%NTRANatera-1.07%+2.75%+22.67%+1.22%+46.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMXMFbioMerieuxN/AN/AN/AN/AN/AN/AN/AN/ACHEOYCochLearN/AN/AN/AN/AN/AN/AN/AN/ALHLabcorp4.73 of 5 stars2.34.02.54.22.52.52.5NTRANatera3.1696 of 5 stars3.53.00.00.02.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMXMFbioMerieux 2.00HoldN/AN/ACHEOYCochLear 2.67Moderate BuyN/AN/ALHLabcorp 2.62Moderate Buy$290.336.16% UpsideNTRANatera 3.06Buy$194.0015.80% UpsideCurrent Analyst Ratings BreakdownLatest CHEOY, LH, NTRA, and BMXMF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025NTRANateraRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$268.008/25/2025LHLabcorpRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$311.008/15/2025NTRANateraStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$183.008/11/2025NTRANateraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$210.00 ➝ $220.008/11/2025CHEOYCochLearZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold8/10/2025NTRANateraMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$195.008/8/2025NTRANateraCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/8/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$190.00 ➝ $210.008/8/2025NTRANateraRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$251.00 ➝ $255.007/28/2025NTRANateraEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$170.007/25/2025LHLabcorpUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$282.00 ➝ $305.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMXMFbioMerieux$4.31B3.85$4.48 per share31.30$38.50 per share3.64CHEOYCochLear$1.53B8.37$2.37 per share41.26$9.66 per share10.11LHLabcorp$13.01B1.75$22.04 per share12.41$101.96 per share2.68NTRANatera$1.70B13.55N/AN/A$9.08 per share18.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMXMFbioMerieux$467.68MN/A0.00∞N/AN/AN/AN/A9/4/2025 (Estimated)CHEOYCochLear$251.82MN/A0.0040.85N/AN/AN/AN/AN/ALHLabcorp$746M$9.0630.1915.591.785.66%15.45%7.02%10/23/2025 (Estimated)NTRANatera-$190.43M-$1.91N/AN/AN/A-12.89%-22.22%-15.03%11/11/2025 (Estimated)Latest CHEOY, LH, NTRA, and BMXMF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NTRANatera-$0.60-$0.74-$0.14-$0.74$476.84 million$546.60 million7/24/2025Q2 2025LHLabcorp$4.14$4.35+$0.21$2.84$3.49 billion$3.53 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMXMFbioMerieuxN/AN/AN/AN/AN/ACHEOYCochLear$1.221.25%N/AN/AN/ALHLabcorp$2.881.05%N/A31.79%N/ANTRANateraN/AN/AN/AN/AN/ALatest CHEOY, LH, NTRA, and BMXMF DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/10/2025LHLabcorpquarterly$0.721.05%8/28/20258/28/20259/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMXMFbioMerieux0.082.201.29CHEOYCochLearN/A2.351.52LHLabcorp0.611.501.32NTRANateraN/A3.723.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMXMFbioMerieuxN/ACHEOYCochLearN/ALHLabcorp95.94%NTRANatera99.90%Insider OwnershipCompanyInsider OwnershipBMXMFbioMerieuxN/ACHEOYCochLearN/ALHLabcorp0.84%NTRANatera5.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMXMFbioMerieux14,600118.36 millionN/ANot OptionableCHEOYCochLear5,155130.80 millionN/ANot OptionableLHLabcorp70,00083.10 million82.40 millionOptionableNTRANatera4,434137.25 million129.52 millionOptionableCHEOY, LH, NTRA, and BMXMF HeadlinesRecent News About These CompaniesMagnetar Financial LLC Buys Shares of 2,669 Natera, Inc. $NTRA1 hour ago | marketbeat.comCanada Pension Plan Investment Board Acquires 63,200 Shares of Natera, Inc. $NTRA1 hour ago | marketbeat.comInsider Selling: Natera (NASDAQ:NTRA) Director Sells 2,750 Shares of Stock2 hours ago | americanbankingnews.comNatera, Inc. $NTRA Shares Sold by Kestra Advisory Services LLC2 hours ago | marketbeat.comMaverick Capital Ltd. Buys 268,715 Shares of Natera, Inc. $NTRASeptember 3 at 7:29 AM | marketbeat.com3,095 Shares in Natera, Inc. $NTRA Acquired by B. Metzler seel. Sohn & Co. AGSeptember 3 at 4:47 AM | marketbeat.comNatera (NASDAQ:NTRA) Director Sells $459,222.50 in StockSeptember 3 at 4:23 AM | insidertrades.comTracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q2 2025 UpdateSeptember 2 at 11:39 PM | seekingalpha.comNatera price target raised to $268 from $255 at RBC CapitalSeptember 2 at 11:39 PM | msn.comNatera: A Buy As Positive Growth And Cashflow Outweigh UnprofitabilitySeptember 2 at 2:40 PM | seekingalpha.comNatera (NTRA) Provides an Update on its Intellectual Property Litigation With NeoGenomicsSeptember 2 at 2:11 AM | insidermonkey.comParnassus Investments LLC Purchases 49,546 Shares of Natera, Inc. $NTRASeptember 1 at 5:26 AM | marketbeat.comDriehaus Capital Management LLC Buys 21,539 Shares of Natera, Inc. $NTRAAugust 31, 2025 | marketbeat.comGordian Capital Singapore Pte Ltd Has $1.36 Million Stock Position in Natera, Inc. $NTRAAugust 31, 2025 | marketbeat.comNatera, Inc. $NTRA Shares Purchased by Trexquant Investment LPAugust 31, 2025 | marketbeat.comItau Unibanco Holding S.A. Buys 10,803 Shares of Natera, Inc. $NTRAAugust 30, 2025 | marketbeat.comRafferty Asset Management LLC Reduces Holdings in Natera, Inc. $NTRAAugust 30, 2025 | marketbeat.comWhy Natera (NTRA) Stock Is Down TodayAugust 29, 2025 | finance.yahoo.comNatera Provides Update on Patent Litigation with NeoGenomicsAugust 29, 2025 | businesswire.comHighTower Advisors LLC Trims Stock Holdings in Natera, Inc. $NTRAAugust 29, 2025 | marketbeat.comWhy Natera (NTRA) Stock Is Up TodayAugust 28, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCan AI Defense Contracts Push Palantir Shares Higher?By Chris Markoch | August 19, 2025Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t IgnoreBy Sam Quirke | August 14, 2025How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?By Jordan Chussler | August 14, 2025Buffett’s Wisdom Could Spell Trouble for Palantir ShortsBy Chris Markoch | August 26, 2025V2X Stock: Defense Underdog Riding a $4.3B Air Force ContractBy Nathan Reiff | August 24, 2025CHEOY, LH, NTRA, and BMXMF Company DescriptionsbioMerieux OTCMKTS:BMXMF$140.25 0.00 (0.00%) As of 09/2/2025bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.CochLear OTCMKTS:CHEOY$97.62 +1.07 (+1.11%) As of 09/3/2025 03:57 PM EasternCochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.Labcorp NYSE:LH$273.49 -0.29 (-0.11%) Closing price 09/3/2025 03:59 PM EasternExtended Trading$273.79 +0.30 (+0.11%) As of 09/3/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.Natera NASDAQ:NTRA$167.53 -1.81 (-1.07%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$167.63 +0.10 (+0.06%) As of 04:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
